Role of Metabolomics in Understanding Drug-Induced Liver Toxicity Mechanisms

Zahra Qureshi^*
*Correspondence: Zahra Qureshi, Department of Biomedical Engineering (BME), National University of Singapore, Singapore 117583, Singapore, Email:

Introduction

Drug-Induced Liver Injury (DILI) remains a leading cause of drug development failures, post-marketing drug withdrawals, and acute liver failure in clinical settings. The liver, being the central organ for drug metabolism and detoxification, is particularly vulnerable to adverse drug reactions. Traditional toxicological methods, including histopathology, clinical chemistry, and enzyme assays, often fall short in detecting early or subtle molecular changes preceding overt liver damage. In this context, metabolomics has emerged as a powerful systems biology tool that enables the comprehensive analysis of small-molecule metabolites in biological samples. By capturing the dynamic metabolic responses of the liver to xenobiotics, metabolomics provides valuable insights into the biochemical perturbations underlying hepatotoxicity. This approach not only facilitates the early detection of DILI but also helps elucidate its mechanisms, identify predictive biomarkers, and support risk assessment in both preclinical and clinical settings [1].

Description

Metabolomics involves the qualitative and quantitative analysis of metabolites in biological fluids, tissues, or cells using advanced analytical techniques such as Nuclear Magnetic Resonance (NMR) spectroscopy, Liquid Chromatography-Mass Spectrometry (LC-MS), and gas Chromatography-Mass Spectrometry (GC-MS). In DILI studies, metabolomics enables the monitoring of metabolic shifts induced by drug exposure, thereby revealing potential toxicity pathways, such as oxidative stress, mitochondrial dysfunction, lipid dysregulation, and bile acid disturbances. For instance, acetaminophen, a widely used analgesic, causes dose-dependent hepatotoxicity due to the accumulation of the reactive metabolite N-Acetyl-P-Benzoquinone Imine (NAPQI). Metabolomic profiling of acetaminophen-treated subjects consistently shows depletion of glutathione, elevation of cysteine-conjugates, and disturbances in energy metabolism, all of which align with known hepatotoxic mechanisms.

Several experimental modelsâ??ranging from isolated hepatocytes and liver organoids to rodent and human clinical studiesâ??have incorporated metabolomics to dissect the mechanisms of DILI. One prominent example includes the identification of early lipidomic changes in the liver prior to histological evidence of damage following treatment with drugs like amiodarone and valproic acid. Such findings highlight the role of disrupted β-oxidation and phospholipid metabolism in liver toxicity. Additionally, perturbations in bile acid composition and urea cycle intermediates have been associated with cholestatic and mitochondrial forms of DILI. These metabolic fingerprints not only reflect drug-specific injury patterns but also help distinguish between intrinsic (dose-related) and idiosyncratic (unpredictable) liver injuries.

Clinical translation of metabolomics in hepatotoxicity monitoring is gaining momentum with the identification of non-invasive biomarkers in serum or urine. Metabolites such as bile acids, taurine-conjugates, kynurenine pathway intermediates, and acylcarnitines have been proposed as early indicators of DILI. These biomarkers offer advantages over traditional liver enzymes like ALT and AST, which often rise only after substantial hepatic injury has occurred. Furthermore, metabolomics can aid in patient stratification based on metabolic phenotype or susceptibility to liver injury, enabling personalized medicine approaches. Regulatory bodies such as the FDA and EMA have also acknowledged the potential of metabolomics in safety assessment and biomarker qualification processes [2].

Conclusion

Metabolomics offers a transformative approach to understanding the complex biochemical pathways involved in drug-induced liver toxicity. By providing a comprehensive snapshot of metabolic disturbances, it reveals early molecular events and mechanistic insights that are often undetectable by conventional toxicological assays. The ability to integrate metabolomic findings with genomic and proteomic data further enhances the predictive power and interpretability of toxicity studies. As the field advances with improvements in analytical sensitivity, data analytics, and standardization, metabolomics will play an increasingly critical role in drug safety evaluation, biomarker discovery, and personalized hepatotoxicity risk prediction. Ultimately, this systems-based approach holds promise not only for minimizing drug attrition but also for improving patient outcomes in clinical pharmacotherapy.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Lichtfuss, Gregor F., Cheng, Wei-Jung, Farsakoglu, Yagmur, et al. "Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation." J Immunol 189 (2012): 1491–1499.

Google Scholar Cross Ref  Indexed at

2. Fogli, Massimo, Costa, Paola, Murdaca, Giuseppe, et al. "Significant NK cell activation associated with decreased cytolytic function in peripheral blood of HIV-1-infected patients." Eur J Immunol 34 (2004): 2313–2321.

Google Scholar Cross Ref  Indexed at